Physician profile
Christopher Fan
NPI 1982067393
$5,505.54
in general payments reported to CMS, 2019-2025
22 companies · $2,926 in 2025
The $2,926 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $669 · 2023: $658 · 2024: $1,252 · 2025: $2,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,836.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,485.47 | 2022-2025 | |
| Janssen Biotech, INC. | $609.43 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $600.42 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $279.00 | 2022-2024 | Zeposia |
| Celltrion USA INC. | $277.01 | 2024-2025 | Vegzelma |
| Pfizer INC. | $197.66 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $155.01 | 2022 | |
| Genzyme Corporation | $154.61 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $119.70 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $119.41 | 2025 | Zenpep, Vowst |
| Janssen Scientific Affairs, LLC | $110.08 | 2024 | Remicade, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.90 | 2022-2024 | Xifaxan |
| Pharmacosmos Therapeutics INC. | $62.19 | 2023 | Monoferric |
| Madrigal Pharmaceuticals | $52.01 | 2025 | Rezdiffra |
| Ardelyx, INC. | $45.21 | 2025 | Ibsrela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $33.49 | 2025 | |
| Merck Sharp & Dohme LLC | $27.77 | 2022-2024 | Dificid |
| Dynavax Technologies Corporation | $26.04 | 2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $24.24 | 2025 | |
| Csl Behring | $21.05 | 2025 | Kcentra |
| Lilly USA, LLC | $18.84 | 2024 | Omvoh |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.